News

France-based pharmaceutical research company Servier has partnered with Intarcia Therapeutics to develop and commercialise its ITCA 650, outside the US and Japan. ITCA 650 is Intarcia's investigational therapy for the treatment of type 2 diabetes. The...

Bristol-Myers Squibb's (BMS) European medical education programme Partnering for Cure has selected four research projects, designed to investigate new ways to cure viral diseases. BMS will provide €300,000 to support the four research projects. The selected...

Cambridge, MA, USA and Krakow, Poland, November 7, 2014 / B3C newswire / -Felicitex Therapeutics, a leader in the diagnostics and development of therapeutics for quiescent cancers, and Selvita (PL: SLV), the largest drug discovery company in Central and...

Munich, Germany, November 7, 2014 / B3C newswire / - Horst Lindhofer, CEO of LINDIS Biotech and inventor of the trifunctional antibody technology succeeded in regaining the relevant IP and know-how from TRION Pharma out of the insolvency proceedings....

Bristol-Myers Squibb (BMS) has expanded its existing biologics manufacturing agreement with Switzerland-based Lonza. The contract is expanded for the production of commercial quantities of a second BMS biologic medicine at Lonza's mammalian manufacturing facility...

ViiV Healthcare, a joint venture of GlaxoSmithKline (GSK), Pfizer and Shionogi, has obtained approval in Canada, for its Triumeq (dolutegravir) 50mg, abacavir 600mg, and lamivudine 300mg) to treat patients with Human Immunodeficiency Virus (HIV-1) infection. ...

The World Health Organisation (WHO) has warned West Africa may face up to 10,000 new Ebola cases per week within two months, due to the increasing number of patients. With a reported death rate...